The Israeli Patent Office has issued Patent No. 193318, “System for Pulmonary Delivery of Alpha-1 Proteinase Inhibitor,” to Kamada and PARI Pharma, Kamada has announced. The patent relates to delivery of Kamada’s inhaled alpha-1 proteinase inhibitor (AAT) using a custom eFlow nebulizer from PARI.
Kamada CEO Amir London commented, “We continue to fortify our leading intellectual property position in AAT technology as well as the systems for its innovative delivery. This new patent expands, strengthens and complements our growing patent portfolio worldwide. Patents such as this are important as they not only protect key elements of our AAT technology to develop a variety of pulmonary treatments that are associated with diseases that can potentially benefit from AAT administration, but they also offer multiple opportunities for monetization through potential drug development partnerships or other licensing arrangements. Separately, this patent strengthens and expands the patent protection for our pulmonary franchise for inhaled AAT in partnership with PARI Pharma and further establishes our global leadership position in plasma-derived protein therapy technology.”
London added that with “the encouraging and important lung function outcomes from our European Phase 2/3 clinical trial of our inhaled AAT to treat AAT Deficient (AATD) patients,” Kamada plans to submit an MAA to the EMA by the end of 2015 and that the EMA “has agreed to evaluate these post hoc analyses from this innovative study.”
Read the Kamada press release.
